DBBIOTE: Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk
Study Details
Study Description
Brief Summary
It is now well documented that changes in gut microbiota composition accompany obesity and type 2 diabetes (T2D) and contribute to low-grade inflammation, insulin resistance,and glucose intolerance. It is not yet clear if T2D predisposes the intestine to allow more microbial products or possibly live bacteria to subvert the gut mucosal barrier. However, it is known that hyperglycemia during T2D induces a more permissive gut barrier allowing increased penetration of microbes and their products into the blood. An important next step is to determine which strains of bacteria promote dysbiosis, allowing bacteria or bacterial components to subvert the gut barrier and alter glucose control. It is hypothesized that gut microbes in the colon and other lower gut segments are key modulators of energy balance, glucose homeostasis and insulin sensitivity.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The gut acts as a barrier to bacteria and nutrients and participates in glucose homeostasis via endocrine actors and the gut-brain-peripheral axis. It is unclear how T2D alters microbes in upper and lower intestine of humans. Studies in animals show that T2D promotes translocation of microbes to the blood and tissues to promote metabolic dysfunction. It is crucial to determine whether bacteria or their components subvert the gut barrier in human T2D, and then to identity the relevant bacterial strains in tissues that control blood glucose. The overall objective of our research program is to demonstrate that specific microbes in the gut, circulation, and key metabolic tissues are involved in the progression of T2D. We will define the microbial signatures of T2D in duodenal biopsies and stool samples by comparing T2D and non-T2D subjects.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Type 2 Diabetes patients Upper gut biopsies and lower gut samples |
Procedure: Endoscopy and duodenal biopsy and sampling
All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
|
| Active Comparator: Non Type 2 Diabetes patients Upper gut biopsies and lower gut samples |
Procedure: Endoscopy and duodenal biopsy and sampling
All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
|
Outcome Measures
Primary Outcome Measures
- Microbial signature [One week]
Compare the bacterial profile of T2D and non-T2D subjects
Eligibility Criteria
Criteria
Inclusion Criteria:
- T2DB de novo or non T2DB patients
Exclusion Criteria:
- oral hypoglycemic agents or lipidlowering or antihypertensive drugs
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | INAF, Université Laval | Québec | Canada | G1V 0A6 |
Sponsors and Collaborators
- Laval University
Investigators
- Principal Investigator: André Marette, PhD, Laval University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CMI2 CHU